(123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis

Cardiac amyloidosis is a rare disorder, but it may lead to potentially life-threatening restrictive cardiomyopathy. Cardiac manifestations frequently occur in primary amyloidosis (AL) and familial amyloidosis (ATTR), but are uncommon in secondary amyloidosis (AA). Echocardiography is the method of c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of nuclear medicine and molecular imaging 2012-10, Vol.39 (10), p.1609-1617
Hauptverfasser: Noordzij, Walter, Glaudemans, Andor W J M, van Rheenen, Ronald W J, Hazenberg, Bouke P C, Tio, René A, Dierckx, Rudi A J O, Slart, Riemer H J A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1617
container_issue 10
container_start_page 1609
container_title European journal of nuclear medicine and molecular imaging
container_volume 39
creator Noordzij, Walter
Glaudemans, Andor W J M
van Rheenen, Ronald W J
Hazenberg, Bouke P C
Tio, René A
Dierckx, Rudi A J O
Slart, Riemer H J A
description Cardiac amyloidosis is a rare disorder, but it may lead to potentially life-threatening restrictive cardiomyopathy. Cardiac manifestations frequently occur in primary amyloidosis (AL) and familial amyloidosis (ATTR), but are uncommon in secondary amyloidosis (AA). Echocardiography is the method of choice for assessing cardiac amyloidosis. Amyloid deposits impair the function of sympathetic nerve endings. Disturbance of myocardial sympathetic innervations may play an important role in the remodelling process. (123)I-MIBG can detect these innervation changes. Patients with biopsy-proven amyloidosis underwent general work-up, echocardiography and (123)I-MIBG scintigraphy. Left ventricular internal dimensions and wall thickness were measured, and highly refractile cardiac echoes (sparkling) were analysed. Early (15 min) and late (4 h) heart-to-mediastinum ratio (HMR) and wash-out rate were determined after administration of MIBG. Included in the study were 61 patients (30 women and 31 men; mean age 62 years; 39 AL, 11 AA, 11 ATTR). Echocardiographic parameters were not significantly different between the groups. Sparkling was present in 72 % of ATTR patients, in 54 % of AL patients and in 45 % of AA patients. Mean late HMR in all patients was 2.3 ± 0.75, and the mean wash-out rate was 8.6 ± 14 % (the latter not significantly different between the patient groups). Late HMR was significantly lower in patients with echocardiographic signs of amyloidosis than in patients without (2.0 ± 0.70 versus 2.8 ± 0.58, p < 0.001). Wash-out rates were significantly higher in these patients (-3.3 ± 9.9 % vs. 17 ± 10 %, p < 0.001). In ATTR patients without echocardiographic signs of amyloidosis, HMR was lower than in patients with the other types (2.0 ± 0.59 vs. 2.9 ± 0.50, p = 0.007). MIBG HMR is lower and wash-out rate is higher in patients with echocardiographic signs of amyloidosis. Also, (123)I-MIBG scintigraphy can detect cardiac denervation in ATTR patients before signs of amyloidosis are evident on echocardiography.
doi_str_mv 10.1007/s00259-012-2187-8
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1080882826</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1080882826</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-e0646889fbe804fed75141308d589b1cde630541d27a52237b73872889cc20243</originalsourceid><addsrcrecordid>eNo1kMtOwzAURC0kREvhA9ggL8vCcH3zsLNEFY9KldjAOnLim2KUxCFOKsLXE6llNYs5M9IMYzcS7iWAeggAmGQCJAqUWgl9xpYylZlQoLMFuwzhC0Bq1NkFWyBqSCHJluxnLTG624qdKaiuyfKGBuO89QW1v1O9H03rrGuJV77nwydxOph6NIPzLfcVL01vnSl5mJrOzPbgSm6ppf5wRFzLyfT1xMNg9sRNM9XeWR9cuGLnlakDXZ90xT6en943r2L39rLdPO5EJzEdBEEap1pnVUEa4oqsSmQsI9A20VkhS0tpBEksLSqTIEaqUJFWOCfKEgHjaMXWx96u998jhSFvXCjnraYlP4ZcggY934LpjN6e0LFoyOZd7xrTT_n_W9Efk7BrBQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1080882826</pqid></control><display><type>article</type><title>(123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Noordzij, Walter ; Glaudemans, Andor W J M ; van Rheenen, Ronald W J ; Hazenberg, Bouke P C ; Tio, René A ; Dierckx, Rudi A J O ; Slart, Riemer H J A</creator><creatorcontrib>Noordzij, Walter ; Glaudemans, Andor W J M ; van Rheenen, Ronald W J ; Hazenberg, Bouke P C ; Tio, René A ; Dierckx, Rudi A J O ; Slart, Riemer H J A</creatorcontrib><description>Cardiac amyloidosis is a rare disorder, but it may lead to potentially life-threatening restrictive cardiomyopathy. Cardiac manifestations frequently occur in primary amyloidosis (AL) and familial amyloidosis (ATTR), but are uncommon in secondary amyloidosis (AA). Echocardiography is the method of choice for assessing cardiac amyloidosis. Amyloid deposits impair the function of sympathetic nerve endings. Disturbance of myocardial sympathetic innervations may play an important role in the remodelling process. (123)I-MIBG can detect these innervation changes. Patients with biopsy-proven amyloidosis underwent general work-up, echocardiography and (123)I-MIBG scintigraphy. Left ventricular internal dimensions and wall thickness were measured, and highly refractile cardiac echoes (sparkling) were analysed. Early (15 min) and late (4 h) heart-to-mediastinum ratio (HMR) and wash-out rate were determined after administration of MIBG. Included in the study were 61 patients (30 women and 31 men; mean age 62 years; 39 AL, 11 AA, 11 ATTR). Echocardiographic parameters were not significantly different between the groups. Sparkling was present in 72 % of ATTR patients, in 54 % of AL patients and in 45 % of AA patients. Mean late HMR in all patients was 2.3 ± 0.75, and the mean wash-out rate was 8.6 ± 14 % (the latter not significantly different between the patient groups). Late HMR was significantly lower in patients with echocardiographic signs of amyloidosis than in patients without (2.0 ± 0.70 versus 2.8 ± 0.58, p &lt; 0.001). Wash-out rates were significantly higher in these patients (-3.3 ± 9.9 % vs. 17 ± 10 %, p &lt; 0.001). In ATTR patients without echocardiographic signs of amyloidosis, HMR was lower than in patients with the other types (2.0 ± 0.59 vs. 2.9 ± 0.50, p = 0.007). MIBG HMR is lower and wash-out rate is higher in patients with echocardiographic signs of amyloidosis. Also, (123)I-MIBG scintigraphy can detect cardiac denervation in ATTR patients before signs of amyloidosis are evident on echocardiography.</description><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-012-2187-8</identifier><identifier>PMID: 22806059</identifier><language>eng</language><publisher>Germany</publisher><subject>3-Iodobenzylguanidine ; Aged ; Amyloidosis - complications ; Amyloidosis - diagnostic imaging ; Cardiomyopathies - diagnostic imaging ; Cardiomyopathies - etiology ; Female ; Gated Blood-Pool Imaging ; Heart - innervation ; Humans ; Male ; Middle Aged ; Myocardial Perfusion Imaging ; Nerve Endings - diagnostic imaging ; Radiopharmaceuticals ; Sympathetic Nervous System - diagnostic imaging ; Ultrasonography</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2012-10, Vol.39 (10), p.1609-1617</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22806059$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Noordzij, Walter</creatorcontrib><creatorcontrib>Glaudemans, Andor W J M</creatorcontrib><creatorcontrib>van Rheenen, Ronald W J</creatorcontrib><creatorcontrib>Hazenberg, Bouke P C</creatorcontrib><creatorcontrib>Tio, René A</creatorcontrib><creatorcontrib>Dierckx, Rudi A J O</creatorcontrib><creatorcontrib>Slart, Riemer H J A</creatorcontrib><title>(123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Cardiac amyloidosis is a rare disorder, but it may lead to potentially life-threatening restrictive cardiomyopathy. Cardiac manifestations frequently occur in primary amyloidosis (AL) and familial amyloidosis (ATTR), but are uncommon in secondary amyloidosis (AA). Echocardiography is the method of choice for assessing cardiac amyloidosis. Amyloid deposits impair the function of sympathetic nerve endings. Disturbance of myocardial sympathetic innervations may play an important role in the remodelling process. (123)I-MIBG can detect these innervation changes. Patients with biopsy-proven amyloidosis underwent general work-up, echocardiography and (123)I-MIBG scintigraphy. Left ventricular internal dimensions and wall thickness were measured, and highly refractile cardiac echoes (sparkling) were analysed. Early (15 min) and late (4 h) heart-to-mediastinum ratio (HMR) and wash-out rate were determined after administration of MIBG. Included in the study were 61 patients (30 women and 31 men; mean age 62 years; 39 AL, 11 AA, 11 ATTR). Echocardiographic parameters were not significantly different between the groups. Sparkling was present in 72 % of ATTR patients, in 54 % of AL patients and in 45 % of AA patients. Mean late HMR in all patients was 2.3 ± 0.75, and the mean wash-out rate was 8.6 ± 14 % (the latter not significantly different between the patient groups). Late HMR was significantly lower in patients with echocardiographic signs of amyloidosis than in patients without (2.0 ± 0.70 versus 2.8 ± 0.58, p &lt; 0.001). Wash-out rates were significantly higher in these patients (-3.3 ± 9.9 % vs. 17 ± 10 %, p &lt; 0.001). In ATTR patients without echocardiographic signs of amyloidosis, HMR was lower than in patients with the other types (2.0 ± 0.59 vs. 2.9 ± 0.50, p = 0.007). MIBG HMR is lower and wash-out rate is higher in patients with echocardiographic signs of amyloidosis. Also, (123)I-MIBG scintigraphy can detect cardiac denervation in ATTR patients before signs of amyloidosis are evident on echocardiography.</description><subject>3-Iodobenzylguanidine</subject><subject>Aged</subject><subject>Amyloidosis - complications</subject><subject>Amyloidosis - diagnostic imaging</subject><subject>Cardiomyopathies - diagnostic imaging</subject><subject>Cardiomyopathies - etiology</subject><subject>Female</subject><subject>Gated Blood-Pool Imaging</subject><subject>Heart - innervation</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myocardial Perfusion Imaging</subject><subject>Nerve Endings - diagnostic imaging</subject><subject>Radiopharmaceuticals</subject><subject>Sympathetic Nervous System - diagnostic imaging</subject><subject>Ultrasonography</subject><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMtOwzAURC0kREvhA9ggL8vCcH3zsLNEFY9KldjAOnLim2KUxCFOKsLXE6llNYs5M9IMYzcS7iWAeggAmGQCJAqUWgl9xpYylZlQoLMFuwzhC0Bq1NkFWyBqSCHJluxnLTG624qdKaiuyfKGBuO89QW1v1O9H03rrGuJV77nwydxOph6NIPzLfcVL01vnSl5mJrOzPbgSm6ppf5wRFzLyfT1xMNg9sRNM9XeWR9cuGLnlakDXZ90xT6en943r2L39rLdPO5EJzEdBEEap1pnVUEa4oqsSmQsI9A20VkhS0tpBEksLSqTIEaqUJFWOCfKEgHjaMXWx96u998jhSFvXCjnraYlP4ZcggY934LpjN6e0LFoyOZd7xrTT_n_W9Efk7BrBQ</recordid><startdate>201210</startdate><enddate>201210</enddate><creator>Noordzij, Walter</creator><creator>Glaudemans, Andor W J M</creator><creator>van Rheenen, Ronald W J</creator><creator>Hazenberg, Bouke P C</creator><creator>Tio, René A</creator><creator>Dierckx, Rudi A J O</creator><creator>Slart, Riemer H J A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201210</creationdate><title>(123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis</title><author>Noordzij, Walter ; Glaudemans, Andor W J M ; van Rheenen, Ronald W J ; Hazenberg, Bouke P C ; Tio, René A ; Dierckx, Rudi A J O ; Slart, Riemer H J A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-e0646889fbe804fed75141308d589b1cde630541d27a52237b73872889cc20243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>3-Iodobenzylguanidine</topic><topic>Aged</topic><topic>Amyloidosis - complications</topic><topic>Amyloidosis - diagnostic imaging</topic><topic>Cardiomyopathies - diagnostic imaging</topic><topic>Cardiomyopathies - etiology</topic><topic>Female</topic><topic>Gated Blood-Pool Imaging</topic><topic>Heart - innervation</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myocardial Perfusion Imaging</topic><topic>Nerve Endings - diagnostic imaging</topic><topic>Radiopharmaceuticals</topic><topic>Sympathetic Nervous System - diagnostic imaging</topic><topic>Ultrasonography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Noordzij, Walter</creatorcontrib><creatorcontrib>Glaudemans, Andor W J M</creatorcontrib><creatorcontrib>van Rheenen, Ronald W J</creatorcontrib><creatorcontrib>Hazenberg, Bouke P C</creatorcontrib><creatorcontrib>Tio, René A</creatorcontrib><creatorcontrib>Dierckx, Rudi A J O</creatorcontrib><creatorcontrib>Slart, Riemer H J A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noordzij, Walter</au><au>Glaudemans, Andor W J M</au><au>van Rheenen, Ronald W J</au><au>Hazenberg, Bouke P C</au><au>Tio, René A</au><au>Dierckx, Rudi A J O</au><au>Slart, Riemer H J A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>(123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2012-10</date><risdate>2012</risdate><volume>39</volume><issue>10</issue><spage>1609</spage><epage>1617</epage><pages>1609-1617</pages><eissn>1619-7089</eissn><abstract>Cardiac amyloidosis is a rare disorder, but it may lead to potentially life-threatening restrictive cardiomyopathy. Cardiac manifestations frequently occur in primary amyloidosis (AL) and familial amyloidosis (ATTR), but are uncommon in secondary amyloidosis (AA). Echocardiography is the method of choice for assessing cardiac amyloidosis. Amyloid deposits impair the function of sympathetic nerve endings. Disturbance of myocardial sympathetic innervations may play an important role in the remodelling process. (123)I-MIBG can detect these innervation changes. Patients with biopsy-proven amyloidosis underwent general work-up, echocardiography and (123)I-MIBG scintigraphy. Left ventricular internal dimensions and wall thickness were measured, and highly refractile cardiac echoes (sparkling) were analysed. Early (15 min) and late (4 h) heart-to-mediastinum ratio (HMR) and wash-out rate were determined after administration of MIBG. Included in the study were 61 patients (30 women and 31 men; mean age 62 years; 39 AL, 11 AA, 11 ATTR). Echocardiographic parameters were not significantly different between the groups. Sparkling was present in 72 % of ATTR patients, in 54 % of AL patients and in 45 % of AA patients. Mean late HMR in all patients was 2.3 ± 0.75, and the mean wash-out rate was 8.6 ± 14 % (the latter not significantly different between the patient groups). Late HMR was significantly lower in patients with echocardiographic signs of amyloidosis than in patients without (2.0 ± 0.70 versus 2.8 ± 0.58, p &lt; 0.001). Wash-out rates were significantly higher in these patients (-3.3 ± 9.9 % vs. 17 ± 10 %, p &lt; 0.001). In ATTR patients without echocardiographic signs of amyloidosis, HMR was lower than in patients with the other types (2.0 ± 0.59 vs. 2.9 ± 0.50, p = 0.007). MIBG HMR is lower and wash-out rate is higher in patients with echocardiographic signs of amyloidosis. Also, (123)I-MIBG scintigraphy can detect cardiac denervation in ATTR patients before signs of amyloidosis are evident on echocardiography.</abstract><cop>Germany</cop><pmid>22806059</pmid><doi>10.1007/s00259-012-2187-8</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier EISSN: 1619-7089
ispartof European journal of nuclear medicine and molecular imaging, 2012-10, Vol.39 (10), p.1609-1617
issn 1619-7089
language eng
recordid cdi_proquest_miscellaneous_1080882826
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects 3-Iodobenzylguanidine
Aged
Amyloidosis - complications
Amyloidosis - diagnostic imaging
Cardiomyopathies - diagnostic imaging
Cardiomyopathies - etiology
Female
Gated Blood-Pool Imaging
Heart - innervation
Humans
Male
Middle Aged
Myocardial Perfusion Imaging
Nerve Endings - diagnostic imaging
Radiopharmaceuticals
Sympathetic Nervous System - diagnostic imaging
Ultrasonography
title (123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T21%3A30%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=(123)I-Labelled%20metaiodobenzylguanidine%20for%20the%20evaluation%20of%20cardiac%20sympathetic%20denervation%20in%20early%20stage%20amyloidosis&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Noordzij,%20Walter&rft.date=2012-10&rft.volume=39&rft.issue=10&rft.spage=1609&rft.epage=1617&rft.pages=1609-1617&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-012-2187-8&rft_dat=%3Cproquest_pubme%3E1080882826%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1080882826&rft_id=info:pmid/22806059&rfr_iscdi=true